of biologically engineered cancer drugs are being priced in the $100,000 range, including therapies from Roche and Eli Lilly & Co. Last week, Bristol-Myers Squibb Co. received approval for a new melanoma drug that will be priced at roughly $120,000 per...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Medicare to pay for $93,000 prostate cancer drug
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
account